Clinical Scorecard: Evaluation of Exosome-like Nanoparticles from Nerium oleander for Treating Triple-Negative Breast Cancer: Initial In Vitro and Network Pharmacology Study

At a Glance

Key Highlights

• NELNs showed significant cytotoxicity against MDA-MB-231 TNBC cells.
• Induction of apoptosis and increased ROS levels were confirmed.
• Molecular docking indicated favorable interactions with cytochrome P450 targets.
• Network pharmacology highlighted key metabolic pathways involved.
• Potential for reduced side effects compared to conventional chemotherapy.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of TNBC should include assessment of ER, PR, and HER2 receptor status.

Management

• Consider alternative therapies such as plant-derived exosome-like nanoparticles for patients with limited response to conventional chemotherapy.

Monitoring & Follow-up

• Monitor for cytotoxic effects and apoptosis in TNBC treatment using NELNs.

Risks

• Conventional chemotherapy may lead to severe side effects including myelosuppression and cardiotoxicity.

Patient & Prescribing Data

Patients diagnosed with triple-negative breast cancer, particularly those experiencing resistance to standard treatments.

Exploration of NELNs as a potential therapeutic option may provide a novel approach to treatment.

Clinical Best Practices

• Integrate network pharmacology approaches to identify potential therapeutic targets.
• Utilize in vitro assays to evaluate the efficacy of new treatment modalities.

Related Resources & Content

• GLOBOCAN 2022 estimates
• Plant-derived ELNs in cancer treatment